Targeted drug combo for untreated follicular lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of three targeted drugs (zanubrutinib, rituximab, and venetoclax) for people with untreated follicular lymphoma. The goal is to see if this combination works better than standard treatments and has manageable side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have follicular lymphoma (grade 1, 2, or 3a) that has not been treated before.
- Your lymphoma must be at stage II, III, or IV and need treatment because of symptoms like fever, night sweats, weight loss, or an enlarged spleen.
- You must have at least one tumor that can be measured on a scan.
- Your overall health must be good enough (ECOG score 0–2) and your blood counts, kidney, and liver function must be within certain limits.
- You cannot have lymphoma that has spread to the brain or spinal cord, or that has changed into a more aggressive lymphoma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three medications (acalabrutinib, lenalidomide, and rituximab) for people with a type of slow-growing lymphoma called follicular lymphoma. The goal is to see if this combination can control the disease and possibly lead to remission.
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) as a first treatment for follicular lymphoma. The goal is to see if this triple therapy works safely and effectively.
This trial tests a combination of targeted therapy (zanubrutinib) and chemotherapy (G-CVP) for people with follicular lymphoma who have not had treatment before. It aims to see if this combination is safe and effective.
This trial tests a combination of three drugs for people with previously untreated follicular lymphoma. The goal is to see if this combination helps control the lymphoma better.
This trial tests a combination of three targeted drugs (zanubrutinib, rituximab, lenalidomide) plus an immunotherapy drug (tislelizumab) for people with follicular lymphoma that has returned or not responded to at least two prior treatments. The goal is to see if this combination is safe and effective.
This study compares two drug combinations for people newly diagnosed with follicular lymphoma. One group gets zanubrutinib plus lenalidomide, and the other gets lenalidomide plus rituximab. The goal is to see which combination works better with acceptable side effects.
Hear when a new Grade 1 Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.